Soleno Therapeutics, Inc. (SLNO) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Redwood City, CA, 美国. 现任CEO为 Anish Bhatnagar.
SLNO 拥有 IPO日期为 2014-11-13, 115 名全职员工, 在 NASDAQ Capital Marke, 市值为 $2.72B.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
